title: Chronic relapsing experimental autoimmune encephalomyelitis: effects of insulin-like growth factor-I treatment on clinical deficits, lesion severity, glial responses, and blood brain barrier defects.
abstract: Chronic relapsing experimental autoimmune encephalomyelitis (crEAE), a model for multiple sclerosis, was used to test 2 regimens of insulin-like growth factor-I (IGF-I) treatment. We induced crEAE by injecting 3x10(7) myelin basic protein-(MBP) sensitized lymph node cells into adult female SJL/J mice. Fifty-one mice, divided randomly into 4 groups, were used in the first trial. Two groups received IGF-I (a gift of Cephalon, Inc.) 0.6 mg/kg/d subcutaneously from day 7 to day 16 and the other two groups received placebo injections. IGF-I treatment reduced clinical deficits during the first attack and during 2 subsequent relapses. Image analysis of immunostained and histological sections showed that IGF-I treatment reduced BBB defects and both the numbers and sizes of inflammatory, demyelinating, and demyelinated lesions. Twelve mice that had recovered from their first attack were used in our second trial to evaluate possible adverse effects of prolonged treatment with a higher dose of IGF-I. Six received 1.2 mg/kg/d for 6 weeks (days 19-63). No adverse effects of IGF-I treatment were identified. The eyes, hearts, livers, and kidneys of IGF-I-treated mice were normal histologically and their spleens also appeared normal except for mild to moderate microscopic increases in lymphopoesis. Our results suggest that prolonged IGF-I treatment is well tolerated and that the anti-inflammatory effects of IGF-I have a major role in reducing clinical deficits and lesion severity in crEAE. These effects, if present in multiple sclerosis, may benefit patients with this disease.
authors.affiliation: Laboratory of Experimental Neuropathology, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: W
authors.initials: W
authors.lastname: Li
authors.forename: L
authors.initials: L
authors.lastname: Quigley
authors.forename: D L
authors.initials: DL
authors.lastname: Yao
authors.forename: L D
authors.initials: LD
authors.lastname: Hudson
authors.forename: M
authors.initials: M
authors.lastname: Brenner
authors.forename: B J
authors.initials: BJ
authors.lastname: Zhang
authors.forename: S
authors.initials: S
authors.lastname: Brocke
authors.forename: H F
authors.initials: HF
authors.lastname: McFarland
authors.forename: H D
authors.initials: HD
authors.lastname: Webster
mesh_terms: D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects / Q000502:physiology; D002908:Chronic Disease; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D007334:Insulin-Like Growth Factor I / Q000627:therapeutic use*; D008264:Macrophages / Q000187:drug effects; D008279:Magnetic Resonance Imaging; D051379:Mice; D008815:Mice, Inbred Strains; D004676:Myelin Basic Protein / Q000276:immunology; D009186:Myelin Sheath / Q000473:pathology; D009416:Nerve Regeneration / Q000187:drug effects; D009457:Neuroglia / Q000187:drug effects*; D015347:RNA Probes; D012008:Recurrence
chemical_list: D004676:Myelin Basic Protein; D015347:RNA Probes; D007334:Insulin-Like Growth Factor I